Idiopathic Short Stature Clinical Trial
Official title:
Pilot Study of Ethiology Research by a Multidisciplinary Evaluation Then a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
Our trial aims to evaluate the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size (taking child gender into account), after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. We propose to perform a two-step study. The first one consists in a standardized multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of ISS is confirmed.
Detailed description: Establishing the etiological diagnosis of short stature is an important step to guide the therapeutic management of patients and to propose appropriate genetic counseling. Short stature can be a symptom of many pathologies. However, in the majority of cases (80%), no specific etiology is found during a pediatric clinical investigation. In this case, the diagnosis of "idiopathic" short stature is performed. However, the diagnostic and therapeutic management of short stature after exclusion of classical pediatric causes is extremely heterogeneous and there are currently no consensual recommendations. We could therefore expect to have a much higher proportion of diagnosed patients with more standardized procedures both clinical and genetic. Additionally, in recent years, new methods of genetic investigation (gene panel, whole exome or whole genome sequencing analysis) have made it possible to identify many genetic variants associated with apparently isolated short stature. So far, none of the publications reporting next-generation sequencing analysis have focused on patients with authentic idiopathic short stature, i.e. without associated bone anomalies or syndromic features, and are often focused on only a subset of target genes. Our trial aims at estimating the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size, after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. We propose to perform a two-step study. The first one consists in a multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of authentic ISS is confirmed. All patients will have: - a pre-inclusion visit - an inclusion visit after which the multidisciplinary clinico-radiological evaluation will be held This analysis will assign patients to the diagnosis of either: 1. non-idiopathic short stature (diagnosis of constitutional bone disease or syndromic disorder) 2. authentic idiopathic short stature A teleconsultation (1) to explain to the parents the conclusions of the multidisciplinary clinico-radiological evaluation. This teleconsultation will be followed for all patients in the "non-idiopathic short stature" group, by a visit to take samples for genetic analysis in the context of clinical care, followed by a teleconsultation (2) to give them and explain the results This teleconsultation will be followed for the first 30 patients in the "authentified idiopathic short stature" group, by a visit to take samples for whole genome analysis in the context of research, followed by a teleconsultation (2) to return the results. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06382155 -
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
|
Phase 2 | |
Recruiting |
NCT05894876 -
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
|
||
Completed |
NCT01246219 -
Short Stature Related Distress
|
Phase 4 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00710307 -
Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
|
||
Completed |
NCT01248416 -
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
|
Phase 3 | |
Completed |
NCT01504802 -
Pharmacodynamics of CNP During Growth Hormone Treatment
|
N/A | |
Completed |
NCT00488124 -
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
|
Phase 2 | |
Withdrawn |
NCT01438801 -
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
|
Phase 4 | |
Recruiting |
NCT06309979 -
A Study to Assess Growth in Children With Idiopathic Short Stature
|
||
Terminated |
NCT00121875 -
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
|
Phase 4 | |
Active, not recruiting |
NCT04020913 -
Skeletal Muscle Effects of GH in Boys
|
||
Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT02973061 -
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
|
||
Completed |
NCT01778023 -
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
|
Phase 3 | |
Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
Active, not recruiting |
NCT00840944 -
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
|
Phase 4 | |
Completed |
NCT01070173 -
Ghrelin Levels in Children With Poor Growth
|
N/A | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|